0001209191-22-040252.txt : 20220701
0001209191-22-040252.hdr.sgml : 20220701
20220701163551
ACCESSION NUMBER: 0001209191-22-040252
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220701
FILED AS OF DATE: 20220701
DATE AS OF CHANGE: 20220701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DILLY STEPHEN GEORGE
CENTRAL INDEX KEY: 0001389147
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 221061962
MAIL ADDRESS:
STREET 1: C/O SIERRA ONCOLOGY, INC.
STREET 2: 1820 GATEWAY DRIVE, SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: (605) 376-8679
MAIL ADDRESS:
STREET 1: 1820 GATEWAY DRIVE
STREET 2: SUITE 110
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-01
1
0001290149
Sierra Oncology, Inc.
SRRA
0001389147
DILLY STEPHEN GEORGE
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DR., SUITE 110
SAN MATEO
CA
94404
1
1
0
0
CEO and President
Common Stock
2022-07-01
4
D
0
5000
55.00
D
0
D
Stock Option (right to buy)
14.03
2022-07-01
4
D
0
520000
0.00
D
2030-06-01
Common Stock
520000
0
D
Stock Option (right to buy)
12.15
2022-07-01
4
D
0
260000
0.00
D
2030-08-12
Common Stock
260000
0
D
Stock Option (right to buy)
16.73
2022-07-01
4
D
0
92000
0.00
D
2031-03-15
Common Stock
92000
0
D
Stock Option (right to buy)
31.54
2022-07-01
4
D
0
165000
0.00
D
2032-03-14
Common Stock
165000
0
D
The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Mary Christina Thomson, Attorney-In-Fact for Stephen George Dilly
2022-07-01